In glioblastoma CSCs, pentyl-3-bromopyruvate ester, another agent blocking glycolysis at the level of HK2, reduced cell stemness, as reflected by the downregulation of CD133, and its coadministration with doxorubicin mitigated the cancer-initiating properties of glioblastoma CSCs in an in vivo murine model [146]. Here, HK2 is linked to glioblastoma.